Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
E7 TCR-T cells · 2 trials · 23 indications
Objective tumor response as measured by RECIST
Proportion of subjects who complete treatment without an event that meets criteria for feasibility failure
| Arm | Type | Description |
|---|---|---|
| E7 TCR-T cells | EXPERIMENTAL | Subjects will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. |
| Name | Type | Description |
|---|---|---|
| E7 TCR-T cells | BIOLOGICAL | Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion. |
| Aldesleukin | DRUG | Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV every eight hours will be administered for up to six doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion. |
Inclusion Criteria: Subjects must meet all the following criteria to participate in this study. 1. Histologically or cytologically confirmed metastatic or refractory/recurrent HPV-16+ cancer. 2. Tumor and/or blood with HPV16 genotype as determined by testing performed in a Clinical Laboratory Impro...
Top 20 of 26 competitors
E7 TCR-T cells is an investigational cell therapy being developed for HPV-associated cancers, including cervical cancer, oropharyngeal squamous cell carcinoma, anal cancer, vulvar cancer, penile cancer, and vaginal cancer. It is currently in Phase 2 clinical development for these indications.
E7 TCR-T cells is a T-cell receptor (TCR) therapy designed to target cells expressing the E7 protein, which is produced by human papillomavirus (HPV). The therapy is intended to recognize and attack HPV-associated cancer cells.
E7 TCR-T cells is being developed by Iovance Biotherapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IOVA.
E7 TCR-T cells is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. A Phase 1 trial is also ongoing as part of its clinical development program.
E7 TCR-T cells is being studied in two recruiting trials in the United States. NCT05686226 is a Phase 2 trial with 20 participants, and NCT05639972 is a Phase 1 trial with 15 participants, both enrolling adults aged 18 and older with HPV-associated cancers.
E7 TCR-T cells is also referred to as E7 TCR-T in clinical trial documentation. Both names refer to the same investigational T-cell receptor therapy targeting HPV-associated cancers.